🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Julie E. Bauman

George Washington University

ORCID: 0000-0002-1398-6636
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 10 papers. Top paper: “Head and neck squamous cell carcinoma”.

Head and neck squamous cell carcinoma

Nature Reviews Disease Primers(2020)10.1038/s41572-020-00224-3
N/A
10.9DataRank · unranked
3996 citations

Barbara Burtness, C. René Leemans, Vivian Wai Yan Lui, Julie E. Bauman, Jennifer R. Grandis +1 more

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005147
N/A
1.7DataRank · unranked
66 citations

Michael J. Pishvaian, Margaret K. Callahan, Amy Weise, Branimir I. Šikić, Osama E. Rahma +19 more

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Clinical Cancer Research(2014)10.1158/1078-0432.ccr-13-3360
N/A
0.598DataRank · unranked
53 citations

Julie E. Bauman, William E. Gooding, William Denq, Sufi M. Thomas, Lin Wang +14 more

Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6015
N/A
0DataRank · unranked
7 citations

Nabil F. Saba, Denise J. Roe, Jessica R. Bauman, John M. Kaczmar, Aarti Bhatia +14 more

STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0744
N/A
0DataRank · unranked
30 citations

Hua Li, Yan Zeng, Jose Rivera, Ning Cheng, Christopher N. Peterson +9 more

Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism

Cell Death and Disease(2022)10.1038/s41419-022-04798-6
N/A
0DataRank · unranked
18 citations

Claudia M. Espitia, Aikseng Ooi, Julie E. Bauman, Jennifer S. Carew, Steffan T. Nawrocki +1 more

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.249
N/A
0DataRank · unranked
2 citations

Peter A. Pinto, Howard L. Parnes, Christian P. Pavlovich, Edward Uchio, Mike Nguyen +13 more

Five- or 10-year colonoscopy for 1-2 non-advanced adenomatous polyps (FORTE) NRG-CC005 study: A randomized phase III non-inferiority trial comparing colorectal cancer incidence in participants with 1-2 non-advanced adenomas randomized to a 5- and 10-year surveillance colonoscopy exam schedule versus a 10-year surveillance colonoscopy exam schedule.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3631
N/A
0DataRank · unranked
1 citations

Hanna Bandos, Douglas Corley, Jeff Dueker, Greg Yothers, Jinbing Bai +6 more

HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine

PEDIATRICS(2023)10.1542/peds.2022-060301
N/A
0DataRank · unranked
15 citations

Anna‐Barbara Moscicki, Heide Woo, Chiu‐Hsieh Hsu, Troy J. Kemp, Lígia A. Pinto +6 more

Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma

Journal of Clinical Investigation(2021)10.1172/jci150335
N/A
0DataRank · unranked
60 citations

Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan +16 more